• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Denise Josephina Johanna Hermans, Constantijn G Bauland, Jeffrey Zweegers, Ingrid Mathilde van Beynum, Catharina Joanna Maria van der Vleuten
  • Medicine
  • The British journal of dermatology
  • 2013 (First Publication: 1 April 2013)
  • BACKGROUND Infantile haemangioma (IH) is a benign, common and self-limiting tumour of infancy; only a minority of cases need active treatment. Currently, propranolol appears superior to classicExpand
  • J.M.P.A. van den Reek, Marcia Tummers, +6 authors E.M.G.J. de Jong
  • Medicine
  • Journal of the European Academy of Dermatology…
  • 2015 (First Publication: 1 March 2015)
  • BACKGROUND Drug survival is an indicator for treatment success; insight in predictors associated with drug survival is important. OBJECTIVES (I) To analyse the long-term drug survival forExpand
  • Jeffrey Zweegers, J M P A van den Reek, +13 authors E.M.G.J. de Jong
  • Medicine
  • The British journal of dermatology
  • 2016 (First Publication: 1 August 2016)
  • BACKGROUND Predictors for successful treatment are important for personalized medicine. Predictors for drug survival of biologics in psoriasis have been assessed, but not split for differentExpand
  • Jeffrey Zweegers, Marisol E. Otero, +6 authors Elke M.G.J. de Jong
  • Medicine
  • Acta dermato-venereologica
  • 2016 (First Publication: 1 May 2016)
  • The efficacy of biologic or conventional systemic therapies for psoriasis has been shown in randomized controlled trials. Effectiveness, however, has been studied in daily practice cohorts, and noExpand
  • J M P A van den Reek, Marieke J. H. Coenen, +9 authors E.M.G.J. de Jong
  • Medicine
  • The British journal of dermatology
  • 2017 (First Publication: 1 May 2017)
  • BACKGROUND The effectiveness of biologics for psoriasis shows heterogeneity among patients. With pharmacogenetic markers, it might be possible to predict treatment response. OBJECTIVES We aimed toExpand
  • J M P A van den Reek, P P M van Lümig, +4 authors Elke M.G.J. de Jong
  • Medicine
  • The Journal of dermatological treatment
  • 2013 (First Publication: 6 May 2013)
  • Background: To increase effectiveness of standard adalimumab treatment 40 mg every other week (EOW) for patients with psoriasis, dose escalation to 40 mg every week or addition of methotrexate (MTX)Expand
  • J M P A van den Reek, Jeffrey Zweegers, +14 authors Elke M.G.J. de Jong
  • Medicine
  • The British journal of dermatology
  • 2014 (First Publication: 1 November 2014)
  • BACKGROUND Drug survival is a marker for treatment success. To date, no analyses relating dermatological quality-of-life measures to drug survival have been published. OBJECTIVES (i) To describeExpand